scholarly journals Interleukin-23 serum level in systemic lupus erythematosus patients: Relation to disease activity and different disease parameters

2022 ◽  
Vol 44 (2) ◽  
pp. 139-143
Author(s):  
Shimaa Rafat ◽  
Yomna Y. Mohamed ◽  
Mai E. Ahmed ◽  
Enas A. Abdelaleem
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Serum Level ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Interleukin 23 ◽  
Disease Parameters

scholarly journals Lack of Association between Serum Interleukin-23 and Interleukin-27 Levels and Disease Activity in Patients with Active Systemic Lupus Erythematosus

2021 ◽  
Vol 10 (20) ◽  
pp. 4788
Author(s):  
Katarzyna Pawlak-Buś ◽  
Wiktor Schmidt ◽  
Piotr Leszczyński
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Disease Activity Index ◽  
Systemic Autoimmune Disease ◽  
Enzyme Linked Immunosorbent Assay ◽  
Systemic Lupus ◽  
Interleukin 27 ◽  
Interleukin 23

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by the production of multiple autoantibodies, resulting in tissue and organ damage. Recent studies have revealed that interleukin-23 (IL-23) and interleukin-27 (IL-27) may be therapeutically relevant in selected SLE manifestations. This study aimed to identify associations between serum IL-27 and IL-23 levels and disease activity in Polish patients with different manifestations of SLE: neuropsychiatric lupus (NPSLE), and lupus nephritis (LN). Associations between interleukin levels and oligo-specific antibodies against double-stranded DNA (dsDNA), dose of glucocorticoids, and type of treatment were also analyzed. An enzyme-linked immunosorbent assay was used to assess anti-dsDNA antibodies and analyze the serum concentration of IL-27 and IL-23 from 72 patients aged 19–74 years with confirmed active SLE. Disease activity was measured using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2-K). No significant correlations between interleukin levels and SLEDAI score, anti-dsDNA, corticosteroid dose, or type of treatment were noted. Patients with NPSLE and LN presented the highest median scores of SLEDAI.

scholarly journals Serum leptin in systemic lupus erythematosus patients: Its correlation with disease activity and some disease parameters

2018 ◽  
Vol 40 (1) ◽  
pp. 23-27 ◽  
Author(s):  
Sahar Fakhreldin Mohammed ◽  
Mayada Ali Abdalla ◽  
Wesam Mustafa Ismaeil ◽  
Marwa Mohammed Sheta
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Serum Leptin ◽  
Disease Parameters

scholarly journals Serum Midkine Levels in Systemic Lupus Erythematosus

2018 ◽  
Vol 6 (8) ◽  
pp. 1323-1327 ◽  
Author(s):  
Blondina Marpaung ◽  
Andi Raga Ginting ◽  
OK Moehad Sjah
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Serum Level ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Systemic Disease ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Significant Difference ◽  
Healthy Control

BACKGROUND: Midkine (MK) induces inflammation and could inhibit inducible regulatory T cell differentiation. These reports suggest that MK may play a role in the pathogenesis of autoimmune disease including SLE, but data about MK in SLE patients was still limited, and the role of Midkine in SLE is largely unknown.AIM: The purpose of this study was to compare serum level MK in SLE patients and control, also analysed the relationship between the serum MK level and disease activity in SLE.METHODS: This cross-sectional study was conducted in Adam Malik Hospital from January-June 2017. Diagnosis of SLE was established according to the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria, and disease activity was assessed using the Mexican Systemic lupus erythematosus disease activity index (MEX-SLEDAI). Subjects with evidence of malignancy and systemic disease (pulmonary, kidney, liver, metabolic disorder, etc.) were excluded. Data analysis was performed using SPSS 22nd version. P < 0.05 was considered statistically significant.RESULTS: There were 90 subjects and divided into 2 groups: SLE patients group (n=40) and healthy control groups (n = 50). Midkine levels were increased in the serum of SLE patients compared by health control. There was a significant difference in the median serum Midkine levels between SLE patients and healthy control (P < 0.001). Elevated Midkine serum levels were a significant difference between active disease and remission (P = 0.018).CONCLUSION: Elevated Midkine serum level could be a marker of SLE disease activity and have a role in the pathogenesis of SLE.

THU0181 Serum level of SYNDECAN-1 is associated with disease activity in patients with systemic lupus erythematosus

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 216.3-217
Author(s):  
K.-J. Kim ◽  
J.-Y. Kim ◽  
S.-J. Park ◽  
I.-W. Baek ◽  
C.-H. Yoon ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Serum Level ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Lupus

Raised serum level of APRIL in patients with systemic lupus erythematosus: Correlations with disease activity indices

2010 ◽  
Vol 135 (1) ◽  
pp. 118-124 ◽  
Author(s):  
M. Hegazy ◽  
H. Darwish ◽  
H. Darweesh ◽  
A. El-Shehaby ◽  
Y. Emad
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Serum Level ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Activity Indices
Sign in / Sign up

Export Citation Format

Share Document